thenewsfacts.com
  • Home
  • Latest News
  • Trending News
  • Entertainment
  • Technology
  • Sports
  • Business
  • Health
thenewsfacts.comthenewsfacts.com
Font ResizerAa
Search
  • Home
  • Latest News
  • Trending News
  • Entertainment
  • Technology
  • Sports
  • Business
  • Health
Follow US
© thenewsfacts : All Rights Reserved.

Home » India Recommends Bharat Biotech’s COVAXIN for Kids Under 12 Years

COVID Vaccines

India Recommends Bharat Biotech’s COVAXIN for Kids Under 12 Years

TheNewsFacts
Last updated: October 12, 2021 5:57 pm
TheNewsFacts
Share
India Recommends Bharat Biotech's COVID19 Vaccine for Kids
SHARE

Bharat Biotech’s COVID-19 vaccine for children under 12 years of age has got India’s Subject Expert Committee nod. This recommendations given by SEC today makes the first vaccine maker in the country to get such an approval after a review of its trial data for the 2-18 age-group.

The decision is a big bolster to India’s vaccination program to not only cover adults but also its younger population. Most importantly, vaccinating children against the coronavirus, having already rolled out more than 950 million doses to adults among its population of nearly 1.4 billion.

Bharat Biotech‘s Covaxin, which uses an inactivated coronavirus with an immunity booster, is among the three shots that are being used in India as part of the vaccination drive for adults.

More than 110 million doses of Covaxin have been administered and the company is in the process of securing an emergency use listing from the World Health Organization, a decision that is expected later this month.

Bharat Biotech Covid 19 vaccine is the first in the world for age group from 2-18 years

COVAXIN
Covaxin for children under 12 year old gets India SEC recommendation

“This represents one of the first recommendations worldwide for COVID-19 vaccines for the 2-18 age group. Bharat Biotech sincerely thanks the DCGI, Subject Experts Committee, and CDSCO for their expedited review process. We now await further regulatory approvals from the CDSCO prior to product launch and market availability of Covaxin for children,” Bharat Biotech said in a statement.

Bharat Biotech has submitted data from clinical trials in the 2-18 years age group for Covaxin (BBV152) to CDSCO. The data has been thoroughly reviewed by the CDSCO and SEC and have provided their positive recommendations, the vaccine maker said.

“After detailed deliberation, the committee recommended grant of market authorisation of the vaccine for the age group of 2 to 18 years for restricted use in emergency situations subject to the certain conditions,” the SEC recommendations stated.

The recommendations have been forwarded to the Drugs Controller General of India (DCGI) for final approval.

TAGGED: BHARAT BIOTECH COVAXIN, Covaxin, Covaxin for Kids
Share This Article
Twitter Email Copy Link Print
Previous Article 5 Reasons why the world loves Neymar? 5 reasons why the world can’t stop loving Neymar?
Next Article Now, 111 Million Fans Play Squid Game, With No More Prank Calls Now, 111 Million Fans Play Squid Game, With No More Prank Calls

Your Trusted Source for Accurate and Timely Updates!

We're committed to providing accurate and unbiased news as it unfolds, earning the trust of a large audience. Stay informed with our news updates on the latest events and trends, keeping you ahead of the curve.
FacebookLike
TwitterFollow
InstagramFollow

Popular Posts

PM Modi Celebrates Netaji’s Birth Anniversary with Bharat Parv

Today, January 23, 2024, marks the 127th birth anniversary of Netaji Subhas Chandra Bose, one…

By TheNewsFacts

New DGCA Caution on International Air Travel Bookings

Indian Aviation regulator DGCA has issued a new advisory and also cautioned International air travellers…

By TheNewsFacts

BTS Jin urges fans to stop sharing his shirtless pictures, to join army service

BTS Jin has urged fans to stop sharing his shirtless photos, he also divulged when…

By TheNewsFacts

You Might Also Like

Dr. Krishna Ella Receives Johns Hopkins Highest Medal of Honor
Latest News

COVAXIN Creator Dr. Krishna Ella Wins Prestigious Johns Hopkins Award

By TheNewsFacts
COVAXIN
Trending News

Covaxin: Facts vs. Fiction – Separating Truth from Misinformation

By TheNewsFacts
Covaxin BHU Study
COVID VaccinesLatest News

Covaxin BHU Study: BB Points Flaws in Data Points, Backs Strong Safety Track Record

By NewsFacts Bureau
COVAXIN safety First
Latest News

COVAXIN Safety Assured: Bharat Biotech Puts Safety First

By TheNewsFacts
thenewsfacts thenewsfacts

About US


TheNewsFacts: Brings you the interesting facts, news facts and updates from India an the world across politics, tech, entertainment, business, tending, and more. We deliver what you love to read.
Top Categories
  • Latest News
  • Trending News
  • Paris Olympics 2024
  • Sports
  • Entertainment
  • Business
  • Technology
Usefull Links
  • About The News Facts
  • Latest News
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Contact Us
Follow us
Facebook Twitter Instagram

© thenewsfacts. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?